학술논문

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
Document Type
Article
Source
In The Lancet Oncology December 2021 22(12):1740-1751
Subject
Primary Research
Articles
Language
ISSN
1470-2045